Does Long-Term Use of Sezome (HepaMed) Pose Risks to Liver or Kidney Health? Is It Safe for Patients with Preexisting Liver Impairment?

Cholestagel (sestamibe) is a selective cholesterol absorption inhibitor approved in China for the management of hypercholesterolemia, particularly as an adjunct to statin therapy or in patients who cannot tolerate statins. Unlike statins—which inhibit hepatic cholesterol synthesis—sestamibe acts locally in the small intestine by blocking the Niemann-Pick C1-like 1 (NPC1L1) transporter, thereby reducing dietary and biliary cholesterol uptake.

Clinical trial data and post-marketing surveillance have not demonstrated clinically significant hepatotoxicity or nephrotoxicity with long-term sestamibe use. In pivotal phase III trials, liver enzyme elevations (ALT/AST) occurred at rates comparable to placebo, and no cases of drug-induced liver injury (DILI), autoimmune hepatitis, or acute liver failure were reported. Similarly, renal safety assessments—including serum creatinine, estimated glomerular filtration rate (eGFR), and urinary albumin-to-creatinine ratio—showed no meaningful deviation from baseline over 52 weeks of treatment.

For patients with preexisting hepatic impairment, caution remains warranted—not because sestamibe is metabolized extensively by the liver (it undergoes minimal hepatic metabolism and is primarily excreted unchanged in feces), but because dyslipidemia itself often coexists with chronic liver disease, such as nonalcoholic fatty liver disease (NAFLD) or compensated cirrhosis. In these populations, lipid-lowering therapy must be individualized: baseline LFTs and monitoring every 3–6 months are recommended, especially when combining sestamibe with other agents. Sestamibe is contraindicated in patients with decompensated cirrhosis or active liver disease with jaundice or coagulopathy.

Renal safety is similarly favorable. No dose adjustment is required for mild to moderate chronic kidney disease (CKD stages 1–3). In patients with severe CKD (stages 4–5) or end-stage renal disease (ESRD), limited pharmacokinetic data exist; however, given sestamibe’s negligible renal excretion (<1% of dose), it is not expected to accumulate. Still, clinical experience in advanced CKD remains sparse, and shared decision-making with nephrology input is advised.

In summary, sestamibe has a well-characterized safety profile with no evidence of intrinsic hepatorenal toxicity. Patients with stable, compensated liver or kidney disease may use it safely under appropriate monitoring—but it is not a substitute for addressing underlying metabolic or inflammatory drivers of organ dysfunction.